Affimed Archives

Home Affimed

Latest Posts

Podcast 1 Sep 2023

Beyond Biotech podcast 61 – Blood Cancer Awareness Month

On this week’s podcast, to recognize Blood Cancer Awareness Month, we have a conversation with Affimed's CMO, Andreas Harstrick, to talk about blood cancers, and what Affimed is doing to…

September 1, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 7 Jun 2017

What Cancer Therapies did European Biotechs Showcase at ASCO 2017?

Here are the most innovative therapies presented by European biotechs fighting cancer during the ASCO 2017 meeting in Chicago. European biotech was in the spotlight during this year's edition of…

June 7, 2017 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Nov 2020

Innate Immunity in Cancer Gains Recognition with Affimed’s €1.8B Deal

Last week’s €1.75B deal between the German biotech Affimed and Swiss giant Roivant backs up an emerging trend of harnessing our innate immune system to treat cancer. According to the…

November 16, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 10 Oct 2018

Cancer Immunotherapy Phase I on Hold After Patient Death

The German biotech Affimed has halted two Phase I trials of its cancer immunotherapy after three patients suffered neurotoxicity due to the treatment, causing the death of one of them.…

October 10, 2018 - 2 minutesmins - By Jonathan Smith

affimed afmd 2015 results immuno oncology

News and Trends 31 Mar 2016

The ‘Formative Year’ of Germany’s only NASDAQ-listed Biotech

Affimed from Heidelberg had a 'formative year' (hmm) in 2015. Major highlights include raising of €52.6M, expanding to the US and advances in the development of its next-generation antibodies for immuno-oncology.…

March 31, 2016 - 2 minutesmins - By Denise Neves Gameiro

biotech nasdaq stock top biopharma finance 2016

News and Trends 23 Feb 2016

7 Trendy European Biotechs Listed on the NASDAQ in 2016

Here are 7 European Biotechs listed on the NASDAQ we thought were worth mentioning in more depth; location, market cap and brief financial and R&D backgrounds. NASDAQ is the second-largest Stock…

February 23, 2016 - 6 minutesmins - By Philip Hemme

merck msd keytruda immunoncology lymphoma hodgkins affimed

News and Trends 26 Jan 2016

Keytruda Combo! MSD Recruits German Biotech on Lymphoma PD-1 Trial

Affimed in Heidelberg (Germany) will fund and conduct a clinical trial to investigate the combination of Merck's (MSD) anti-PD-1 therapy (Keytruda), with Affimed's proprietary drug for the treatment of patients with…

January 26, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 24 Nov 2015

Money Money Money for Immuno-Oncology: BMS Joins up with a Top German VC

The World Leader in the Immuno-Oncology field has teamed up with a major German Investor to better identify breakthrough investment opportunities across the EU. Bristol-Myers Squibb (BMS) has partnered with…

November 24, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 19 Oct 2015

Secret Shareholder racks up another €19.2M for Affimed’s Cancer Tandem Antibodies

Affimed Therapeutics is a clinical-stage biopharmaceutical company from Heidelberg (Germany) which is developing highly targeted cancer immunotherapies for some leukemias and Hodgkin's Lymphoma. An undisclosed shareholder has just increased its…

October 19, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 3 Sep 2014

Affimed secures almost $30M in Financing to continue its clinical development

Affimed Therapeutics today announced that it has closed a $15.7 million (€11.7 million) Series E equity funding led by Affimed’s current investors Aeris Capital, BioMedInvest, LSP Life Sciences Partners, Novo…

September 3, 2014 - 2 minutesmins - By Joachim Eeckhout

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

Download Inpart’s latest report

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering